Here are the DEF 14A proxy statements from Unicycive Therapeutics, Inc. (UNCY) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow UNCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UNCY filings page.
Unicycive Therapeutics, Inc. is asking stockholders to vote at its June 19, 2026 annual meeting on two main items: electing three directors (Shalabh Gupta, M.D., Sandeep Laumas, M.D., and Saraswati Kenkare‑Mitra, Ph.D.) and ratifying Grassi & Co. CPAs, P.C. as auditor for 2026.
Stockholders of record at the close of business on April 27, 2026, when 26,700,027 common shares were outstanding, are entitled to one vote per share. A majority of these shares, or 13,341,637, is needed for a quorum. The Board currently has a combined Chair/CEO structure, with Gupta serving as both.
The proxy describes Nasdaq independence determinations, committee structures and recent resignation of independent director Gaurav Aggarwal, M.D., with plans to appoint a new independent director and committee member by October 3, 2026 under Nasdaq grace periods. It also outlines executive pay, including 2025 total compensation of $2,391,621 for the CEO, largely from option awards, and severance and change‑in‑control protections.